Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Zhejiang Zhenyuan Share Co., Ltd. specializes in the production of generic pharmaceuticals, with a significant presence in the Chinese healthcare market. The company differentiates itself through its extensive portfolio of over 200 products, particularly in the cardiovascular and anti-infective segments, which are critical in addressing the growing healthcare demands in China.
Zhejiang Zhenyuan generates revenue primarily through the sale of generic drugs, benefitting from lower production costs and a broad distribution network across China. Its competitive advantages include a strong R&D pipeline and established relationships with healthcare providers, allowing for effective market penetration.
Regulatory approvals for new generic drugs
Changes in healthcare policies affecting drug pricing
Market share shifts in the Chinese pharmaceutical sector
Raw material cost fluctuations impacting margins
Regulatory changes that could impact drug approval processes
Technological disruption in drug manufacturing
Intense competition from both domestic and international generic drug manufacturers
Potential for price erosion in key therapeutic areas
Negative net income leading to potential liquidity issues
Low operating cash flow could limit investment in growth opportunities
moderate - The pharmaceutical sector is somewhat insulated from economic downturns, but overall healthcare spending is influenced by GDP growth.
Interest rates affect Zhenyuan's financing costs for R&D and expansion, potentially impacting profitability and valuation multiples.
minimal - The company has a low debt-to-equity ratio (0.10), indicating limited reliance on external financing.
value - Investors may be attracted to the low valuation metrics despite the current operational challenges.
high - The stock has shown significant price fluctuations, evidenced by a 26.6% decline over the past three months.
